Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.20

-5.5%

Nov 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (8000)	3/12/2003 1:01:18 AM
From: JMarcus	Read Replies (2) of 52153

There's a helpful article on EPIX's MS 225 at diagnosticimaging.com. The author quotes Robbie Stephens' Wade King at pegging <<the potential U.S. market for intravascular contrast media, including their use in coronary artery imaging, at $75 million annually. MS-325 could have that market all to itself initially, assuming it receives FDA marketing clearance for use in the aortoiliac arteries in early 2003, as the company hopes.>> Well, hope springs eternal, but EPIX still appears to have a good lead. A $75M annual market is certainly a small fraction of the $8B spent on angiogram procedures. Perhaps King is underestimating the market potential. Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next